ClinicalTrials.gg

Program

ixoberogene soroparvovec

Also written as “6E11 vg/eye of ADVM-022”, “2E11 vg/eye of ADVM-022” and “ADVM-022”.

Its studies are mostly in Diabetic Retinopathy · Blindness, led by Eli Lilly.

Furthest: phase 2, since May 28, 20202 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly20 open or runningphase 2since May 28, 2020Nov 19, 2018none ahead
  • Named in Eli Lilly’s own pipeline as Ixoberogene Soroparvovec (Ixo-Vec), phase 3, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 19, 2018First study: phase 1 study in BlindnessFirst studyNCT03748784 · 30 enrolled · United States
  2. May 28, 2020Phase 2 study in Diabetic RetinopathyNCT04418427 · 36 enrolled · United States, Puerto Rico

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04418427Diabetic Retinopathy · United States, Puerto Rico2CompletedNov 22, 202236
NCT03748784Blindness · United States1CompletedJun 22, 202230

How it is read

Names in the registry

  • “6E11 vg/eye of ADVM-022”, 1 entry
  • “2E11 vg/eye of ADVM-022”, 1 entry
  • “ADVM-022”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.